Zymeworks Boosts 2026 Outlook with Theravance Biopharma Acquisition…

Event summary

Zymeworks updated 2026 financial guidance following the acquisition of Theravance Biopharma, expecting total revenue of $278M–$292M and Adjusted EBITDA of $114M–$128M.
The acquisition adds YUPELRI® (revefenacin) to Zymeworks’ portfolio, providing a 35% share of net U.S. profits and royalties on net sales outside the U.S.
Zymeworks retained Theravance Biopharma’s commercial organization for YUPELRI and plans to hire a seasoned pharmaceutical executive to lead commercial operations.
The acquisition was financed through a $350M non-recourse note from OMERS and $217.5M of existing cash resources.
Zymeworks expects a potential $100M milestone payment related to TRELEGY ELLIPTA in Q1 2027.

The big picture

Zymeworks’ acquisition of Theravance Biopharma aligns with its strategy to build a diversified portfolio of revenue-generating assets while advancing innovative medicines. The deal provides immediate accretive revenue and cash flow, positioning Zymeworks to leverage its existing R&D and operational infrastructure. The biotech sector is increasingly focused on asset aggregation to drive durable cash flows, and Zymeworks’ move underscores this trend. The integration of YUPELRI and other assets will be critical to realizing the anticipated benefits.

What we're watching

Revenue Growth: Whether YUPELRI’s 25% growth in hospital sales can be sustained and drive continued margin expansion.
Integration Risk: How effectively Zymeworks integrates Theravance Biopharma’s commercial organization and R&D assets.
Financial Flexibility: The pace at which Zymeworks utilizes Irish tax attributes to generate additional value from future revenues and acquisitions.